Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
51 hedge funds and large institutions have $25.5M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more capital invested
Capital invested by funds: $24.3M → $25.5M (+$1.24M)
2% more funds holding
Funds holding: 50 → 51 (+1)
9% less call options, than puts
Call options by funds: $162K | Put options by funds: $179K
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$515K |
| 2 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$311K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$270K |
| 4 |
EGA
Eagle Global Advisors
Houston,
Texas
|
+$242K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$671K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$430K |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$331K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$292K |
| 5 |
Morgan Stanley
New York
|
-$203K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BG
51
Bellevue Group
Kuesnacht,
Switzerland
| – | -$331K | -50,000 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$69K | -11,500 | Closed |
|
|
FAM
53
Formidable Asset Management
Cincinnati,
Ohio
| – | -$5K | -862 | Closed |
|
JNP Hedge Fund Activity: Q2 2016 in Review
51 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q2 2016, worth a combined $25.5M — up 5.1% from $24.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new JNP positions and 3 closed out — a net gain of 1 holder — while 11 added to existing stakes and 17 trimmed.
The largest buyer was Heartland Advisors, adding an estimated $515K. The largest seller was GSA Capital Partners, cutting an estimated $671K.
- 51 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q2 2016, up from 50 in Q1 2016.
- Funds reported $25.5M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q2 2016, up 5.1% quarter-over-quarter.
- 4 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q2 2016 and 3 closed out, a net change of +1 holder.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q2 2016 was Heartland Advisors, an estimated $515K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q2 2016 was GSA Capital Partners, an estimated $671K sold.
Based on aggregated 13F filings for Q2 2016.